S
orafenib, an oral multikinase inhibitor, is approved by the US Food and Drug Administration for the treatment of patients with unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC). 1 In phase III studies, patients treated with single-agent sorafenib showed a significant advantage for progression-free survival (PFS) compared with placebo (in RCC) and an overall survival benefit (in HCC). [2] [3] [4] [5] [6] An overall survival benefit was also observed in patients with RCC when data were censored for placebo-assigned patients who had crossed over to sorafenib treatment. 6 Promising results from phase II studies with single-agent sorafenib in patients with iodinerefractory differentiated thyroid cancer (DTC; median PFS ¼ 79 weeks) [7] [8] [9] [10] prompted initiation of the randomized, placebo-controlled, phase III DECI-SION study, which reached completion in December 2012. 11, 12 Sorafenib is currently being evaluated in other phase II and phase III clinical trials, which include treatment as part of multimodality care (HCC) and in combination with chemotherapeutic agents (metastatic breast cancer). 13 The recommended starting dose for sorafenib in patients with HCC and RCC is 400 mg (two tablets) given orally twice a day, without food. 1 In the recently reported final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib), a non-interventional phase IV study in patients with HCC, data showed that the average daily dose of sorafenib was slightly higher in patients with Child-Pugh B (741.5 mg) than with Child-Pugh A (677 mg), but overall, dosing was generally consistent across patients regardless of Child-Pugh status. 14 In the phase II and phase III DTC studies, the starting dose is 400 mg, twice a day. [7] [8] [9] [10] However, treatment interruptions and/or dose reductions may be warranted to manage some adverse events (AEs). The most common AEs related to sorafenib treatment that may impact quality of life (QOL) include handfoot skin reaction (HFSR), rash (often occurring as a papular, erythematous eruption that can involve extremities, as well as the trunk), upper and lower gastrointestinal (GI) distress, and fatigue 1, 15 ( Tables 1 and 2) .
Hypertension (HTN), another AE that is commonly observed, does not directly affect QOL, while AEs that are less common or are rare but of concern include cardiovascular events (other than HTN, and including congestive heart failure, myocardial ischemia and/or infarction, hypertensive crisis, and QT prolongation), portal HTN and variceal bleeding, wound healing, and squamous cell carcinoma of the skin. 1 Patients with visceral-organ (RCC and HCC) and non-visceral-organ (DTC) disease may have different challenges (eg, patients with HCC often have underlying cirrhosis, and patients with RCC may have HTN and hypercalcemia, while patients with DTC may have hypocalcemia). Furthermore, with declining health, there is an increase in AEs overall, 16, 17 which may or may not be directly related to treatment with sorafenib.
In contrast, patients with non-visceral-organ disease (ie, DTC) are relatively healthy and may be treated long-term with sorafenib. Therefore, the approach to management of AEs may vary by patient population and by length of treatment. Regardless of the patient population, however, the successful management of AEs may allow patients to tolerate the full dose of sorafenib, thereby enabling patients to remain on the sorafenib treatment and maintain a good QOL.
Data presented here include safety outcomes from the pivotal phase III sorafenib (single-agent) studies that supported its approval by the US Food and Drug Administration for use in patients with HCC and RCC. This article also includes outcomes from the phase II DTC (single-agent) trial, which has been completed and published, met its primary end point, and led to the phase III study. Recommendations for the management of common AEs in patients taking sorafenib are provided per the clinical experience of the authors, as well as per further guidance from the literature.
SORAFENIB-RELATED AEs

Hand-Foot Skin Reaction
HFSRs, which are usually Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or 2 (see Table 3 ), can have a significant effect on patient QOL. HFSRs generally appear within the first 6 weeks of sorafenib treatment 1 but may occur as early as 1-2 weeks following treatment initiation.
1,18
Management Approach
The main goal for the management of HFSR is to allow patients to maintain their sorafenib dose for as long as is indicated. This may be accomplished through patient education and proactive management, which often include keeping hands and feet moisturized with a thick urea-based cream, 19 removing thick calluses (hyperkeratosis), wearing comfortable shoes with minimal pressure points, and avoiding hot water 18, [20] [21] [22] [23] [24] (see Table 3 ). The cornerstone of management is to keep skin well hydrated, remove calluses regularly, and use pain medication as needed.
Based on the clinical experience of the authors, it is highly recommended that clinicians see patients in 2-week intervals for the first 2 months following sorafenib initiation to proactively manage HFSR. With grade 1 or 2 HFSR, patients generally can continue sorafenib treatment without any changes to dose or administration. 1 Intolerable grade 2 HFSR that does not improve following one or two dose holidays or a grade 3 episode (eg, patient unable to walk) may require dose reduction. 25 HFSR does not tend to worsen after 3 months of sorafenib treatment. In a subgroup analysis of the phase III TARGET (Treatment Approaches in Renal Cancer Global Evaluation Trial) trial in patients with RCC, the overall incidence of HFSR tended to peak after the first cycle (29%), with fewer cases reported subsequently (16%, 3%, and 1%, during cycles 2, 3, and 4, respectively). Grade 3/4 HFSR, when it did occur, also developed most frequently in early cycles (cycles 1-5 and 7). 26 In a phase II trial of patients with DTC who were treated with sorafenib (N ¼ 55), HFSR severity peaked at treatment cycle 2 and declined by cycle 6 (39% and 10% of patients had grade 2-3 HFSR in cycles 2 and 6, respectively); 17 patients (31%) required dose reduction due to HSFR. 27 With proper management, beginning at the earliest signs of HFSR, patients may be guided over the toughest period and continue therapy, without sorafenib dose reductions or interruptions in therapy. 
Rash
Rash is common in patients treated with sorafenib 2,6,10 (see Tables 1 and 2 ) and presents as a macular or papular rash over the extremities and sometimes over the trunk, often occurring in the first month of treatment. 26 In the phase II sorafenib DTC study, rash severity peaked at cycle 1 and declined by cycle 3 (19% and 5% of patients had grade 2-3 rash in cycles 1 and 3, respectively). 27 Overall, the severity and prevalence of skin AEs (including rash and HFSR) reached a steady state following cycle 12. Of the 30 (55%) patients who required dose reductions because of skin AEs, 31% were able to resume their full dose of sorafenib by the end of the study.
Management Approach
Most rashes are not painful and resolve on their own, and patient education is all that is required. Rashes that cause discomfort may respond to a change to mild, perfume-free soaps; increased emollient applications; avoidance of hot water; and/or wearing loose, natural fabric clothing. 29 Published data suggest that topical corticosteroids may have some efficacy early in therapy when the rash is mild. In addition, although antihistamines (eg, Benadryl [McNeil-PPC, Inc., Fort Washington, PA]) may be considered, they have shown minimal efficacy. 30 Severe rash in four patients treated by the authors was resolved by a short course of oral corticosteroids (unpublished data); however, no clinical trial data exist at this time to support the use of this approach.
Upper and Lower GI Distress
Epigastric Pain: Dyspepsia
Upper GI effects are often caused by reflux or dyspepsia, and grade 1 or grade 2 dyspepsia symptoms commonly occur in patients treated with sorafenib 1,2,6,10 (see Tables 1 and 2) . Epigastric pain, which may affect patients over the long term, can cause appetite loss and anorexia, which may lead to (sometimes severe) weight loss.
Management Approach. Management of dyspepsia (Table 4) is generally similar between tumor types and may be controlled via a low-fiber diet, changes in the timing of sorafenib dosing to always occur before a meal, and the use of supplements, such as probiotics and digestive enzymes. If these approaches are ineffective, the addition of a proton pump inhibitor 22 and sucralfate (Carafate; Aptalis Pharma US, Bridgewater, NJ) suspension, which is indicated for the treatment of peptic ulcers 37 and also has been shown to be effective in patients with gastroesophageal reflux disease (GERD), 38 may be helpful. However, recent recommendations based on strength of evidence for the superiority of proton pump inhibitors over sucralfate for GERD management indicates that there may be little role for sucralfate in the nonpregnant patient with GERD. 39 
Diarrhea
Diarrhea is often associated with sorafenib therapy and is most commonly CTCAE grade 1/2 1,2,6,10 (see Tables 1 and 2 ). Diarrhea may begin early in treatment (immediately or up to 8 weeks) in patients with visceralorgan disease. In the TARGET trial in patients with RCC, diarrhea tended to develop early (within 1 month), and the overall incidence of diarrhea rose during early cycles of sorafenib treatment (23%, 23%, 29%, and 39% in cycles 1, 2, 3, and 4, respectively). 26 However, in patients with DTC, diarrhea often occurs much later; approximately 3-4 months after the initiation of sorafenib treatment. In DTC, onset of diarrhea may be slow and then remain constant, aggravated primarily by poor dietary choices. The authors have observed that, regardless of tumor type (RCC, HCC, DTC), episodes of diarrhea occur intermittently (eg, 2-3 days per week) in the majority (80%) of patients; however, in HCC, ⁎ Only the phase II single-agent sorafenib study, which was completed, met its primary end point, was published, and led to a phase III study, is included in this table.
† Patients in the DTC phase II study received sorafenib 400 mg orally twice a day;
‡ Palmar-plantar erythema.
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; DTC, radioactive iodine-refractory differentiated thyroid cancer; HFSR, hand-foot skin reaction. Management Approach. The treatment approach for diarrhea (see Table 4 ) is similar across tumor types and generally includes dietary adjustments, symptomatic control of diarrhea, and monitoring/ managing electrolytes. In the experience of the authors, the need to reduce or interrupt the sorafenib dose for grade 1 or 2 events is rare. When symptomatic treatment for diarrhea is needed, most patients are able to obtain good control on a single drug, such as loperamide, which can be increased until control is achieved. However, for patients with HCC who are taking lactulose, their dose may be decreased.
Fatigue
Fatigue was frequently reported in patients in the sorafenib phase III (HCC and RCC) and phase II (DTC) clinical studies 2, 6, 10 (see Tables 1 and 2) . Fatigue is generally self-limited, commonly occurring in the first 4-6 months of sorafenib treatment and often resolving after approximately 5-6 months on treatment (author experience). In patients with HCC, however, it is often unclear whether the fatigue is drug-related or due to the underlying liver disease or other cancer treatment, such as recent or ongoing transcatheter arterial chemoembolization procedures. 41 Management Approach. Because fatigue may be symptomatic of other underlying issues, patients should be evaluated for other treatable contributing factors, including emotional distress (ie, depression, anxiety), adverse events of other medications, pain, anemia, sleep disturbances, nutritional issues (ie, weight or food intake changes, imbalances in fluids/electrolytes), decreased physical activity, and comorbid conditions (ie, alcohol/substance abuse; infection; cardiac, endocrine, gastrointestinal, hepatic, neurologic, pulmonary, or renal dysfunction). 42 Medication is generally not needed for patients with fatigue. 42 Unlike HFSR and diarrhea, fatigue associated with sorafenib is likely to resolve around month 6 without treatment or dose adjustment.
Educating patients regarding what to expect and how to adjust their schedules accordingly is usually the key to managing symptoms of fatigue (Table 5 ).
Hypertension and Other Cardiovascular Issues
Hypertension HTN has been reported to occur at a higher incidence in patients with DTC 10 than in patients • DTC: cholestyramine is contraindicated as it negatively impacts synthroid/ levothyroxine replacement. If used, take at night to minimize drug interactions • Cholestyramine is also contraindicated in patients with complete biliary obstruction Sorafenib dose reductions
• Sorafenib dose reduction (to 400 mg qd or every other day) or interruption may be necessary for unmanageable or grade 3 or 4 diarrhea until diarrhea returns to baseline or grade 1
Abbreviations: bid, twice a day; DTC, radioactive iodine-refractory differentiated thyroid cancer; GI, gastrointestinal; HCC, hepatocellular carcinoma; NSAID, nonsteroidal antiinflammatory; qd, once per day; RCC, renal cell carcinoma; tid, three times a day.
with HCC 2 and RCC 6 (see Tables 1 and 2 ); however, this may be the product of longer treatment duration in patients with DTC. Also, it should be noted that data for DTC are phase II, while data from the HCC and RCC trials are phase III and thus more mature. Recent data from a retrospective cohort study of 101 patients with advanced solid tumors who were treated with sorafenib (400 mg twice daily for ≥12 weeks) in a randomized discontinuation trial showed that an increase in systolic blood pressure (SBP) as well as the mean amplitude of change were significantly greater in RCC patients than in non-RCC patients. 43 In this study, 72% and 32% of RCC and non-RCC patients, respectively, developed an ; therefore, blood pressure (BP) should be monitored regularly (at least once a week) at the start of sorafenib therapy. Although some patients are hypertensive before treatment with sorafenib and may already be taking antihypertensive medications, patients with advanced cirrhosis (eg, in HCC) are characteristically hypotensive as a result of peripheral vasodilation, which occurs in approximately half of hospitalized patients with cirrhosis and ascites. 44, 45 Therefore, it is possible that sorafenib may actually help to normalize BP in some of these patients. Diarrhea, which may lead to dehydration and hypotension, can mask HTN, which may reappear when diarrhea is corrected. Once HTN is well controlled, it often does not need to be readdressed, and the dose of sorafenib does not generally have to be adjusted. 46 
Other Cardiovascular Risks
There are additional cardiovascular risks with the long-term (41 year) use of sorafenib; these include both thromboembolic and cardiac ischemic events. The relative risk of tyrosine kinase inhibitor-associated arterial thromboembolic events (ATEs) appears to differ by tumor type. In large clinical trials of patients with HCC (N ¼ 297) and RCC (N ¼ 451), the relative risk (95% confidence interval) of acquiring an ATE compared with placebo was 2.03 (0.62-6.68) and 6.00 (1.35-26.66 ), respectively. The difference compared with control groups was significant in patients with RCC (P ¼ .019) but not with HCC (P ¼ .242). 47 In a study of cardiac safety in patients with RCC, a 2% incidence in left ventricular ejection fraction decline was observed in patients with RCC. 48 Management Approach. For HTN and all cardiovascular AEs, patient education is extremely important. Patients should be continually reminded of cardiac adverse events and to report symptoms to their healthcare team immediately. Treatment recommendations may vary by tumor type (Table 6 ); however, HTN should generally be managed according to standard medical practice, 1 following guidelines by the Joint National Committee for the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). 49 
Portal HTN and Variceal Bleeding
Variceal bleeding, which is associated with portal HTN, is HCC-specific and is not sorafenib-related. Although uncommon, variceal bleeds can be significant in patients with HCC and may be caused by cirrhosis or hepatitis C infection in the presence of cirrhosis. In patients with HCC enrolled in the phase III SHARP (Sorafenib HCC Assessment Randomized Protocol) trial, the risk of variceal bleeds was no different between the sorafenib (2%) and placebo (4%) groups. 2 Overall, the risk for bleeding events in all tumor types (including HCC, RCC, and DTC) has been rare; therefore, it should not be a reason for withholding sorafenib treatment or surgery (Table 7) . Routine variceal screening and prophylaxis as standard of care in patients with cirrhosis should be employed.
Wound Healing
Although the risk of poor wound healing is low with sorafenib therapy, it still elicits concern among clinicians. Fistula formation, which occurs in o1% of patients with HCC and RCC 1 can often appear at the site of prior surgery and radiation. Primarily out of concern for decreased perfusion leading to poorer wound healing, recommendations are to stop sorafenib treatment 24 hours before surgery 1 and restart once wound healing is well established. The authors note that, contrary to recommendations in the US prescribing information, 1 they have not stopped sorafenib therapy before surgery (eg, emergency surgery) and have not observed any issues with wound healing.
Other AEs
Mucositis complications and oropharyngeal toxicities (usually grade 1 or grade 2) have been observed in 30% to 40% of patients with RCC, 6 as well as in 47% of patients with DTC, 10 and may manifest as mouth ulcers, mouth sensitivities, and lesions in the mouth. use of either magic mouthwash; salt and sodium bicarbonate; or chlorhexidine. However, differences in efficacy between types of mouthwash were not statistically significant. 53 There also may be a concern that the numbing effect from the lidocaine in magic mouthwash may make swallowing difficult for some patients. 54 
CONCLUSIONS
Proactive and effective management of AEs that may occur during treatment with sorafenib will allow patients to remain on their prescribed dose, thereby maximizing its therapeutic benefit. For patients with RCC and HCC, in the absence of cirrhosis or with Child-Pugh A cirrhosis and good performance status, starting on a full sorafenib dose is recommended. 1 The starting dose under review in patients with DTC is also 400 mg twice per day.
Physicians can help patients by reviewing potential AEs with them prior to beginning therapy, emphasizing effective management strategies. Patients should be encouraged to call their healthcare team between visits to quickly address issues of toxicity. Overall, patient education and empowerment, both prior to and during sorafenib therapy, is of primary importance in helping to prevent and manage AEs, such as HFSR and diarrhea. Patients also should be reminded to proactively monitor their BP and, with long-term sorafenib use, remain aware of and report cardiac symptoms without delay.
Through effective management of AEs that commonly occur during treatment with sorafenib, patients may enjoy a better QOL and receive full benefit of their sorafenib treatment.
